Loading
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Previous close
$8.09
+$0.10 · +1.25%
Pre-market
$7.95
−$0.14 · -1.73%
Oct 9, 6:10 AM ET
Regular session · ET · Market data may be delayed.
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Day range
Current $8.09
52-week range
Current $8.09
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
91
Deep Value
Sentiment
63
Bullish
Risk
50
Elevated Risk
Momentum
78
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Day range
Current $8.09
52-week range
Current $8.09
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
Avantis U.S. Small Cap Value ETFAVUV4.23M0.01%30.54B USD0.25%$120.13+0.84%
First Trust Dow Jones Select MicroCap Index FundFDM712.18K0.27%260.47M USD0.65%$89.059+1.01%
Dimensional - US Small Cap ETFDFAS326.77K0.00%33.8B USD0.31%$78.10+0.23%
Dimensional - US Targeted Value ETFDFAT265.96K0.00%30.26B USD0.33%$67.56+0.72%
iShares Micro-Cap ETFIWC241.72K0.02%1.32B USD0.60%$182.79-0.31%
Avantis U.S. Small Cap Equity ETFAVSC220.59K0.01%3.06B USD0.25%$69.96+0.47%
Avantis U.S. Equity ETFAVUS142.69K—14.77B USD0.15%$130.06-0.11%
Hartford Multifactor Small Cap ETFROSC95.09K0.20%47.07M USD0.34%$53.96+0.28%Avantis U.S. Small Cap Value ETFAVUVFirst Trust Dow Jones Select MicroCap Index FundFDMDimensional - US Small Cap ETFDFASDimensional - US Targeted Value ETFDFATiShares Micro-Cap ETFIWCAvantis U.S. Small Cap Equity ETFAVSCAvantis U.S. Equity ETFAVUSHartford Multifactor Small Cap ETFROSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
